IL33 and neoplasm: IL-25 promotes tumorigenesis through activating ILC2s which sustain tumour M-MDSCs to suppress T cell and IFNγ-mediated anti-tumour immunity.IL-33 deficiency is associated with a reduction in tumour Tregs and mast cells.